Immunomodulatory effect of Unani polyherbal formulation - Tiryaq Wabai in mild to moderate COVID-19 patients – A randomized placebo-controlled clinical trial

Simple item page
dc.contributor.authorKumar, Ansulen_US
dc.contributor.authorKhan, Mohd Saifen_US
dc.contributor.authorUl Haque, Zeyaen_US
dc.contributor.authorRai, Arpitaen_US
dc.contributor.authorFazil, Mohammaden_US
dc.contributor.authorRabbani, Gulamen_US
dc.date.accessioned2024-11-30T08:13:49Z
dc.date.available2024-11-30T08:13:49Z
dc.date.issued2024-03
dc.description.abstractBackground: The pathogenesis of COVID-19 includes an integrated immune-inflammatory response. Modulation of host immune responses against the SARS-CoV-2 virus might be effective therapeutic management. Various Unani formulations have an immunomodulatory effect. Objective: To explore the immunomodulatory effect and safety of Unani polyherbal drug (Tiryaq Wabai) in COVID-19 patients. Materials and methods: The current study was a randomized placebo-controlled clinical trial that included 92 mild to moderate COVID-19 patients randomized into two groups. The Unani formulation Tiryaq Wabai (2 gm orally once a day) was used as an intervention for 45 days, while the control group received a placebo. Both groups received standard care treatment. The primary outcome was 50% increment in absolute lymphocyte count (ALC). The secondary outcome was 50% increment in mean lymphocyte percentage, CD4 cells, and CD8 cell count. The mean increase in all the above parameters has also been studied. Relevant statistical tests were used to analyze the effect. Results: A statistically significant improvement in a 50% increase in ALC (p-value, 0.004), lymphocyte percentage (p-value, 0.056), CD4 (p-value, 0.005), and CD8 cell count (p-value, 0.050) was reported. Also, a significant improvement in the mean value of the lymphocyte percentage (p-value 0.0007), ALC (p-value 0.0022), CD4 cell count (p-value 0.0025), and CD8 cell count (p-value 0.0093) was observed after the treatment. One adverse event of mild grade was reported in the placebo group. The analysis of safety parameters (LFT and KFT) was normal for both groups. Conclusion: In mild to moderate COVID-19 patients, Tiryaq Wabai effectively showed immunomodulatory activity by improving ALC count, lymphocyte percentage, CD4, and CD8 cell count.en_US
dc.identifier.affiliationsDepartment of CTVS. Rajendra Institute of Medical Sciences (RIMS), Bariatu, Ranchi, 834009, Indiaen_US
dc.identifier.affiliationsDepartment of Critical Care Medicine, New Trauma Centre & Central Emergency. Rajendra Institute of Medical Sciences (RIMS), Bariatu, Ranchi, 834009, Indiaen_US
dc.identifier.affiliationsDepartment of CTVS. Rajendra Institute of Medical Sciences (RIMS), Bariatu, Ranchi, 834009, Indiaen_US
dc.identifier.affiliationsDepartment of Oral Medicine and Radiology, Dental Institute. Rajendra Institute of Medical Sciences (RIMS), Bariatu, Ranchi, 834009, Indiaen_US
dc.identifier.affiliationsHakim Ajmal Khan Institute of Literary and Historical Research in Unani Medicine, CCRUM, Jamia Millia Islamia Campus, New Delhi, 110025, Indiaen_US
dc.identifier.affiliationsMedical Officer. CHC-Karra, Khunti, Jharkhand, 835209, Indiaen_US
dc.identifier.citationKumar Ansul, Khan Mohd Saif, Ul Haque Zeya, Rai Arpita, Fazil Mohammad, Rabbani Gulam . Immunomodulatory effect of Unani polyherbal formulation - Tiryaq Wabai in mild to moderate COVID-19 patients – A randomized placebo-controlled clinical trial. Journal of Ayurveda and Integrative Medicine. 2024 Mar; 15(2): 1-8en_US
dc.identifier.issn0975-9476
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/236927
dc.languageenen_US
dc.publisherElsevier B.V.en_US
dc.relation.issuenumber2en_US
dc.relation.volume15en_US
dc.source.urihttps://doi.org/10.1016/j.jaim.2024.100903en_US
dc.subjectCOVID-19en_US
dc.subjectRandomized controlled trialen_US
dc.subjectUnanien_US
dc.subjectTiryaq wabaien_US
dc.subjectImmunomodulatory drugsen_US
dc.titleImmunomodulatory effect of Unani polyherbal formulation - Tiryaq Wabai in mild to moderate COVID-19 patients – A randomized placebo-controlled clinical trialen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
jaim2024v15n2p1a.pdf
Size:
1.28 MB
Format:
Adobe Portable Document Format
Download
Collections
Journal of Ayurveda and Integrative Medicine